The purpose of the Ninth International Lung Cancer Congress is to update participants on advances in the field of lung cancer, including biology, staging, and multimodality therapy. The 9th Annual International Lung Congress will discuss current trends in surgical, radiotherapeutic, and chemotherapeutic approaches for lung cancer and provide a perspective on clinical data presented at major international oncology meetings. An ongoing focus will be the individualization of therapy based on patient and tumor characteristics. Areas of controversy in lung cancer therapy, including treatment of early-stage and locally advanced disease, testing for molecular markers, and the optimal combination of targeted and cytotoxic agents, will be the subject of panel discussions and debates. This meeting will also feature presentations on optimizing the application of established targeted agents, as well as introducing emerging targeted agents, including mechanism of action and clinical/preclinical results. The format of the congress will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, question-and-answer sessions, as well as translational workshops focusing on future strategies for lung cancer treatment.

At the conclusion of this congress, you should be able to:

• Discuss current and future approaches to staging in NSCLC
• Review current issues in the surgical treatment of NSCLC
• Evaluate approaches to optimize lung cancer therapy based on patient and tumor characteristics
• Summarize the data on the efficacy of adjuvant chemotherapy for patients with early-stage NSCLC
• Describe multimodality therapeutic approaches for patients with stage III NSCLC
• Discuss the current status of various chemotherapy combinations in the treatment of newly diagnosed and relapsed/refractory advanced NSCLC
• Assess approaches to optimizing the use of agents inhibiting signaling through the epidermal growth factor receptor pathway
• Evaluate the optimal use of antiangiogenic agents in NSCLC
• Discuss the various molecular-targeted therapies that are being developed in lung cancer
• Assess how radiation therapy is being sequenced with and integrated into other treatment modalities
• Evaluate results from recent trials investigating current strategies to treat SCLC and mesothelioma
• Summarize the impact of gender on lung cancer therapy
• Describe treatment approaches for elderly and poor–performance status patients
• Apply pertinent data from national and international Cooperative Group trials to the treatment of patients with lung cancer

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 21.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Luncheon symposium Wednesday, June 18:
Physicians’ Education Resource designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.